Clinical trials: Colonic Neoplasm
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Neoplasms, Colorectal Cancer
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
This study will evaluate the safety, tolerability and preliminary efficacy of MK-8353 when administered in combination with pembrolizumab (MK-3475).
- Trial name
- NCT02972034
- Testing
- MK-8353, Pembrolizumab
- Where
- 3 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Colorectal Neoplasms
Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic…
- Trial name
- NCT02198274
- Testing
- BIBH 1
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Metastatic Colorectal Cancer, Solid Tumor
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
The purpose of the study is to assess the safety and tolerability of GC1118 in combination with irinotecan or FOLFIRI in order to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D)
- Trial name
- NCT03454620
- Testing
- irinotecan, FOLFIRI
- Where
- 6 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Carcinoma
A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer
The main purpose of this observational study with Irinotecan onkovis is to determine the number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose under the special circumstances of ambulant…
- Trial name
- NCT01840280
- Where
- 5 sites in Germany
- Volunteers
- 324 people
- Sponsor
- Onkovis GmbH
Colorectal Cancer
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
This observational study will evaluate the safety and efficacy of Bevacizumab in combination with 5-Fluorouracil based chemotherapy as first-line and second-line therapy in Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT01319877
- Where
- 24 sites in China
- Volunteers
- 609 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasm, Iron Deficiency Anemia
Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard…
- Trial name
- NCT00199277
- Testing
- i.v. iron sucrose, Oral iron
- Where
- 5 sites in Spain
- Volunteers
- 150 people
- Sponsor
- J. Uriach and Company
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Colorectal Cancer
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
This is a prospective-retrospective study to determine if the expression of the miRNA's miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from anti-EGFR therapy in stage III Colon Cancer.
- Trial name
- NCT03362684
- Testing
- Cetuximab, FOLFOX
- Volunteers
- 1,808 people
- Sponsor
- IntegraGen SA
Metastatic Colorectal Cancer
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways.
- Trial name
- NCT03206151
- Testing
- CMAB009, Irinotecan, Folinic acid
- Where
- 2 sites in China
- Volunteers
- 520 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Cancer
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer.
- Trial name
- NCT00009737
- Testing
- 5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]
- Where
- 133 sites in United States, Argentina and 12 more
- Volunteers
- 1,987 people
- Sponsor
- Hoffmann-La Roche
Advanced Cancer, Metastatic Cancer
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
- Trial name
- NCT05557045
- Testing
- JZP815
- Where
- 15 sites in United States
- Volunteers
- 98 people
- Sponsor
- Jazz Pharmaceuticals
Metastatic Colorectal Cancer
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
- Trial name
- NCT02568046
- Testing
- Sym004, FOLFIRI
- Where
- 8 sites in United States, Spain
- Volunteers
- 10 people
- Sponsor
- Symphogen A/S
CRC, Colorectal Cancer
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants…
- Trial name
- NCT07805551
- Testing
- HDM2017, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Metastatic Liver Cancer, Secondary Liver Cancer
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.
- Conditions
- Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
- Trial name
- Prometheus (NCT00510627)
- Testing
- Radiofrequency Ablation (RFA), Chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-438162 (MEK162). This study has 3 parts.
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00959127
- Testing
- ARRY-438162 (MEK162), MEK inhibitor; oral
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.